Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies.
about
Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domainIntrabody and Parkinson's diseaseProtective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virusSegregation of NF-kappaB activation through NEMO/IKKgamma by Tax and TNFalpha: implications for stimulus-specific interruption of oncogenic signalingIdentification of CD4 and transferrin receptor antibodies by CXCR4 antibody-guided Pathfinder selection.Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particlesBaculovirus display of single chain antibody (scFv) using a novel signal peptideRecombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries.Overview on the use of therapeutic antibodies in drug discovery.Phages and HIV-1: from display to interplay.Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication.Genetic therapy for HIV/AIDS.A fully human scFv phage display library for rapid antibody fragment reformattingCombined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid AssemblyGene therapy progress and prospects: novel gene therapy approaches for AIDS.Impact of Tat Genetic Variation on HIV-1 DiseaseIn vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat.Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).Genetic therapies against HIV.State of the art in tumor antigen and biomarker discovery.Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants.Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors.Targeting HIV transcription: the quest for a functional cure.Induction of the HIV-1 Tat co-factor cyclin T1 during monocyte differentiation is required for the regulated expression of a large portion of cellular mRNAs.Development of temperature-sensitive mutants of the Drosophila melanogaster P-TEFb (Cyclin T/CDK9) heterodimer using yeast two-hybrid screeningIntracellular antibodies and cancer: new technologies offer therapeutic opportunities.Dominant negative mutant cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat.Keystone symposia: antibody-based therapeutics for cancer.
P2860
Q24634375-1BF23285-C36A-4C8C-B6C0-A9C4B2D84A1FQ24653530-1998A68F-1F6D-40E1-B7D9-202F63B32A8BQ27472711-B9D5E83E-75AE-4B6E-9701-A9F6D3B51C81Q28586249-F294A573-9711-4FA3-A1A3-278B1A04FF7BQ31026565-E2569278-6BB5-4BF0-A726-70FB434B8312Q31155271-2906CABA-B93D-417F-BC1E-8ACD65B411AFQ33368648-1A536A08-CD06-49EA-AD59-7360B73E85A3Q33751786-F3170C4E-2808-49F3-A48E-4934D8CCBEDCQ33886564-440F740F-EA43-4C85-9F80-2DF6EEF4E1A1Q34033739-2A0D045B-4073-4AA5-8F03-B55F69005E01Q34147273-42796111-6698-4E2E-B76D-067882EACFCEQ34273397-4F2475F1-DC0F-44A0-818F-5AC6F502B9C0Q34350400-A67309AC-DE2C-40CB-B8FF-7D05B6D61001Q35207524-0C710F2B-1FF2-4BFD-AEDD-67283D5EEC67Q35635839-84B650DF-BD36-4077-BA66-608A8E99554BQ36030091-7D675AD5-5E03-4034-A0ED-1190D6EDEAA7Q36036704-EA9F0882-9C51-41D4-83A2-6DDEB2BD4E84Q36148507-CE21FB2B-4C20-4F3D-B02D-D3D9A92BF10AQ36228890-3CA55C0B-0B66-43AF-9DD5-EEC46314E618Q36602721-5769257C-5F1E-4F99-B45C-EC1D9ADAEF04Q36954414-B9C6890B-0AE1-4BF8-B457-0E6CBB7A470BQ37027170-65B1D6B2-BED0-4672-A16F-E4D2BDAB36F0Q37132800-60C3EFBA-CCC7-40F7-9E30-EFDCEAF902B4Q37376530-0DBF0863-537E-48DD-A64B-84F4288BC0E0Q38212101-9BDED5F0-F86E-42E0-8F4A-2FAB0137D71EQ38366762-A3AAA3CC-4518-4D16-9DB5-1D0686630245Q38518336-BF6C632A-DD06-41C3-965D-C084E255FA7AQ39395062-AAC9F074-427C-4C68-83AB-346633D2AF98Q39864280-352D2881-3742-4AE1-907D-8DA5B5E523A5Q41320056-D8CDF91B-50E8-4CC0-B074-350271436384Q53303155-6C78EF79-4874-4FE2-B4B0-00AC325B0B60
P2860
Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@ast
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@en
type
label
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@ast
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@en
prefLabel
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@ast
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@en
P2093
P2860
P356
P1476
Inhibition of Tat-mediated tra ...... an anti-hCyclinT1 intrabodies.
@en
P2093
Aimeé St Clair Tallarico
Dongsheng Zhang
Francesca Gennari
Jianhua Sui
Jirong Bai
Rui Ying Zhu
Wayne A Marasco
P2860
P304
P356
10.1074/JBC.M208297200
P407
P577
2002-10-24T00:00:00Z